2023 World Conference on Lung Cancer (Posters)-EP12.01. Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations

EP12.01. Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations - PDF(Slides)

Back to course

Pdf Summary

In this study, the efficacy and safety of aumolertinib, a novel third-generation EGFR tyrosine kinase inhibitor (TKI), were evaluated as neoadjuvant and adjuvant therapy for patients with unresectable stage IIIA-IVA non-small cell lung cancer (NSCLC) with EGFR mutations. The primary endpoint of the study was the objective response rate (ORR), and secondary endpoints included the feasibility of surgery, R0 resection rate, major pathologic response (MPR) rate, pathological complete response (pCR) rate, downstaging rate, event-free survival (EFS), disease-free survival (DFS), and safety.<br /><br />A total of 10 patients were retrospectively analyzed in the neoadjuvant treatment group. Neoadjuvant aumolertinib for 8-14 weeks achieved a higher ORR, pCR rate, and MPR rate compared to historical data from other EGFR-TKIs. All patients underwent surgery, and minimally invasive surgery rates were 100%. In the adjuvant treatment group, 90% of patients had no symptoms of tumor recurrence and continued aumolertinib.<br /><br />The adverse events (AEs) observed during neoadjuvant aumolertinib were grade 1-2, with rash and diarrhea being the most common AEs. No grade 3 AEs occurred during neoadjuvant treatment. <br /><br />The study concluded that neoadjuvant and adjuvant aumolertinib showed satisfactory efficacy with an excellent safety profile in patients with unresectable NSCLC. Importantly, all patients achieved conversion from unresectable to resectable status, including those with stage IVA disease. The study suggests that prolonging the neoadjuvant treatment duration may further enhance response rates, improve surgical feasibility, and prolong progression-free survival (PFS) and overall survival (OS).<br /><br />The authors expressed gratitude to the study participants, their families, caregivers, study team members, and all staff involved in the trial.

Asset Subtitle

ShenCun Fang

Meta Tag

Speaker ShenCun Fang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

aumolertinib

EGFR tyrosine kinase inhibitor

neoadjuvant therapy

adjuvant therapy

non-small cell lung cancer

EGFR mutations

objective response rate

surgery feasibility

pathologic response rate

adverse events